ASCO 2022 | HER2CLIMB-05: tucatinib with trastuzumab and pertuzumab as maintenance therapy for HER2+ mBC
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, describes the rationale and study design of HER2CLIMB-05 (NCT05132582), an ongoing Phase III trial evaluating tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for patients with HER2-positive metastatic breast cancer (mBC). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Transcript (edited for clarity)
So HER2CLIMB-05 is a so-called maintenance strategy. So really incorporating tucatinib earlier in patient’s treatment course than they would receive it with capecitabine, trastuzumab and tucatinib.
Erika
So this takes patients that are on first line taxane with trastuzumab and pertuzumab, and we typically give six to eight cycles of taxane and then we drop the chemo out and we just continue the Trastuzumab and pertuzumab, and if the patients have hormonal expression, typically we add endocrine therapy at that point as well...
So HER2CLIMB-05 is a so-called maintenance strategy. So really incorporating tucatinib earlier in patient’s treatment course than they would receive it with capecitabine, trastuzumab and tucatinib.
Erika
So this takes patients that are on first line taxane with trastuzumab and pertuzumab, and we typically give six to eight cycles of taxane and then we drop the chemo out and we just continue the Trastuzumab and pertuzumab, and if the patients have hormonal expression, typically we add endocrine therapy at that point as well.
So what this study is testing is when that taxane gets dropped out to add tucatinib to the HER2 agents to really see whether we can allow patients to stay on this first line therapy for longer, and also to look at whether we may decrease the down-the-road incidence of brain metastases.
Read more...
